Copyright ©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 14, 2013; 19(10): 1527-1540
Published online Mar 14, 2013. doi: 10.3748/wjg.v19.i10.1527
Table 2 Results of clinical trials with probiotics in ulcerative colitis
Ref.Patients (n)Duration of therapyProbiotic strainsDose (CFU/d)Outcomes
Kruis et al[118]12012 wkEscherichia coli Nissle 191750 × 1010Maintaining the remission (similar to 5-ASA)
Rembacken et al[119]1161 yrEscherichia coli Nissle 19175 × 1010Induction of remission (similar to 5-ASA); maintaining of relapses (similar to 5-ASA)
Venturi et al[120]201 yrVSL3®5 × 10¹¹Maintaining the remission
Ishikawa et al[121]211 yrMilk with bifidobacteria10 × 108Maintaining the remission
Guslandi et al[122]254 wkSaccharomyces boulardii250 mg × 3Induction of remission
Kruis et al[123]3271 yrEscherichia coli Nissle 19172.5-25 × 109Induction of remission (5-ASA better than probiotic)
Tursi et al[124]908 wkBalsalazide/VSL3®900 × 108Induction of remission
Cui et al[125]308 wkBifidobacteria1.26 g/dMaintaining of remission
Kato et al[126]2012 wkBifidobacterium-fermented milk vs placebo109CDAI lower in Bifidobacterium fermented milk that in placebo
Furrie et al[127]184 wkBifidobacterium longum + prebiotic (Synergy 1)4 × 10¹¹Induction of remission
Bibiloni et al[128]326 wkVSL3®1800 billion × 2Induction of remission
Zocco et al[129]18712 moLactobacillus GG vs mesalazina18 × 109No difference between the treatment groups
Henker et al[130]3412 moEscherichia coli Nissle 19175 × 1010Maintenance of remission
Miele et al[131]2912 moVSL3®450-1800 × 109Induction of remission (92.8% in treated with VSL3® and 36.4% in the placebo group)
Sood et al[132]14712 wkVSL3®3.6 × 10¹²Induction of remission (42.9% against 15.7% in the placebo group)
Matthes et al[133]574 wkEscherichia coli Nissle 191710-40 × 108Induction of remission
Sang et al[134]13 RCTsHeterogenity between the studies in their methodology and results